“Physicians should consider discontinuing drugs that may be effective and otherwise appropriate but whose potential harms outweigh the benefits that patients can reasonably expect before death occurs.”
That’s according to the authors of a new study of more than 500,000 older adults which found, over the course of the final year of life, the proportion of individuals exposed to ≥10 different drugs rose from 30.3 per cent to 47.2 per cent. Analgesics, anti-thrombotic agents, diuretics, psycholeptics and β-blockers were the five most commonly used drug classes. More than a fifth received angiotensin-converting enzyme inhibitors and 15.8 per cent received statins during their final month of life.
Writing in the American Journal of Medicine the authors said polypharmacy raises important ethical questions about the potential futility of treatments close to death. “People with life-limiting illness often receive medications whose benefit is unlikely to be achieved within their remaining lifespan,” they said.
While deprescribing is supported by a growing body of evidence, the authors said firm guidelines are needed to support physicians in their decision to continue or discontinue drug treatments near the end of life. When deprescribing does occur, it requires “timely dialogue” with patients and their families, they said.